Driven by a series of policies, China's traditional Chinese medicine industry is in a strategic opportunity for revival. According to the National Bureau of Statistics, in 2022, China's traditional Chinese medicine pharmaceutical industry (production of proprietary Chinese medicines and processing of traditional Chinese medicinal tablets) developed steadily, achieving an annual revenue of about 730.4 billion yuan from the main business, and realising a profit of about 91.5 billion yuan, demonstrating a strong development resilience.